Search
Paclitaxel Treatment Options
A collection of 2016 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
289 - 300 of 2016
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Active Not Recruiting
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: HonorHealth, Scottsdale, Arizona +35 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Active Not Recruiting
The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2)
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/13/2025
Locations: University of California LA, Los Angeles, California +77 locations
Conditions: Triple Negative Breast Neoplasms
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Completed
Phase I:
To determine the safety, toxicity and efficacy profiles of intravesically administered Abraxane at the Maximum Tolerated Dose.
To assemble tissue bank to assess molecular correlates for response to intravesical Abraxane therapy. The antibodies analyzed will include p53, p63, Stathmin, Tau and Ki67.
Phase II:
To evaluate the utility (potential for clinical efficacy) of Abraxane in the treatment of refractory non-muscle invasive and a subset of T2 TCC of the bladder as measured by res... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Herbert Irving Pavillion 11th Floor, New York, New York
Conditions: Bladder Cancer
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Active Not Recruiting
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: City of Hope, Duarte, California +161 locations
Conditions: Head and Neck Cancer
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Active Not Recruiting
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Research Site, Fort Myers, Florida +71 locations
Conditions: Metastatic Breast Cancer
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Active Not Recruiting
The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. The study will also evaluate whether or not intratumoral injection of LOAd703 will support current standard of care treatment to reduce the size of the tumor and improve survival of the patients.
Adenoviruses are known as the "common cold" virus and most individuals have had multiple infections during their lifetime. Oncolytic adenoviruses are adenoviruses that are mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Pancreatic Cancer
'ADVANCE' (A Pilot Trial)
Active Not Recruiting
This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
02/12/2025
Locations: City of Hope National Medical Center, Duarte, California +4 locations
Conditions: Breast Cancer
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Active Not Recruiting
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Alaska Womens Cancer Care ( Site 1016), Anchorage, Alaska +72 locations
Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Recruiting
This First-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with other therapies (cemiplimab, docetaxel, or a cytotoxic T-lymphocyte-associated protein 4 \[CTLA4\] antibody \[another investigational medicinal product\]) in patients with advanced or metastasized non-small cell lung cancer (NSCLC) and unresectable NSCLC after chemoradiotherapy (CRT). Furthermore, the trial aims to establish the safety a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Norton Cancer Institute, Louisville, Kentucky +37 locations
Conditions: Non-Small Cell Lung Cancer
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients with Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Not Yet Recruiting
This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy \[SMMART\])-adaptive clinical treatment \[ACT\]) works in treating patients with sarcoma, prostate, breast, ovarian or pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). SMMART testing uses genetic and protein tests to learn how cancer changes and to understand what drug... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Recruiting
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Arizona Oncology Associates, PC, Tucson, Arizona +63 locations
Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer
Active Not Recruiting
This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Fallopian Tube Transitional Cell Carcinoma, Ovarian Seromucinous Carcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma
289 - 300 of 2016